"Onswik offers a significant convenience for adults with type 2 diabetes, potentially reducing the burden of daily injections without compromising blood sugar control, though it’s not a substitute for daily insulin in terms of efficacy."
The U.S. Food and Drug Administration (FDA) has granted approval to Onswik (insulin efsitora alfa-gobe), a novel long-acting insulin designed for once-weekly injection. This development marks a significant advancement in the management of type 2 diabetes for adults, offering a more convenient alternative to the daily basal insulin regimens currently available. Approved alongside diet and exercise recommendations, Onswik aims to alleviate the logistical challenges associated with daily injections, thereby potentially improving adherence and the overall patient experience in managing this chronic condition. The FDA’s 2026 novel drug approvals list officially recorded the approval on September 23rd, with Eli Lilly, the pharmaceutical manufacturer, announcing the news the following day. It is crucial to note that Onswik is specifically indicated for adults with type 2 diabetes and is not recommended for individuals with type 1 diabetes due to an elevated risk of severe hypoglycemia. Furthermore, its safety and efficacy in pediatric populations have not yet been established.
Onswik’s primary appeal lies in its convenience for adults transitioning from daily basal insulin. Clinical trials conducted by Eli Lilly have demonstrated that Onswik provides comparable blood sugar lowering effects to existing daily insulin formulations, rather than offering superior efficacy. This aligns with its intended role as a more manageable option, not a more potent one. Onswik’s approval positions it as the second weekly basal insulin to receive authorization in the United States, following closely behind Novo Nordisk’s Awiqli, which was approved in March of the same year. This burgeoning class of once-weekly insulins signals a shift towards patient-centered innovations in diabetes care, prioritizing ease of use and reduced treatment burden.
The efficacy and safety profile of Onswik has been rigorously evaluated through four Phase 3 QWINT clinical trials, which collectively involved over 3,400 adults diagnosed with type 2 diabetes. According to Eli Lilly’s official announcement, these trials consistently met their primary endpoint, demonstrating the noninferiority of Onswik in reducing hemoglobin A1C (A1C) levels when compared to daily basal insulins, specifically insulin glargine and insulin degludec. Noninferiority, in this context, means that Onswik was not found to be meaningfully worse than the comparator treatments, falling within a pre-defined margin of 0.4 percentage points.
The comparative A1C reductions observed in the trials were remarkably close. For instance, in the QWINT-1 trial, participants treated with Onswik experienced an average A1C decrease of 1.19 percentage points after 52 weeks, compared to a 1.16-point reduction with insulin glargine. Similarly, in the QWINT-4 trial, the respective drops were 1.01 and 1.00 percentage points, as reported by HCPLive. While the incidence of moderate-to-severe low blood sugar events was lower with Onswik in the QWINT-1 trial, this difference was not statistically significant across the other three studies. In the QWINT-3 trial, serious adverse events were reported in 16% of Onswik users and 11% of insulin degludec users, with cardiovascular-related events being the most prevalent in both treatment groups, as detailed in research published in ScienceDirect.
A notable finding from the QWINT-1 trial, particularly relevant for individuals initiating insulin therapy, was the reduced need for dose adjustments. Patients starting insulin for the first time required a median of two dose adjustments on Onswik, in contrast to eight adjustments with insulin glargine. This simplification could be a significant benefit for patients who find frequent insulin titration challenging to manage. Onswik dosing typically begins at 100 units per week, with fixed increments to 150, 250, and 400 units administered at four-week intervals as needed, offering a structured approach to titration. Furthermore, the QWINT-2 trial indicated that the time spent within the target blood glucose range was slightly higher with Onswik (64.3%) compared to insulin degludec (61.2%).
It is important to acknowledge that the QWINT trials were randomized, open-label studies, meaning both participants and their healthcare providers were aware of the assigned treatment. These trials were sponsored by Eli Lilly, and their findings were published in prestigious medical journals: QWINT-1 and QWINT-2 in The New England Journal of Medicine, and QWINT-3 and QWINT-4 in The Lancet. While these studies collectively affirm Onswik’s ability to achieve comparable blood sugar control to daily insulin, they do not suggest that it is inherently safer or more effective.
The restriction of Onswik for individuals with type 1 diabetes is a critical consideration. People with type 1 diabetes produce little to no insulin endogenously, making them particularly vulnerable to rapid and severe fluctuations in blood glucose levels. The prescribing information explicitly warns of an increased risk of severe hypoglycemia in this population, underscoring the need for careful patient selection and vigilant monitoring.
Common side effects associated with Onswik include hypoglycemia (low blood sugar), allergic reactions, and injection site reactions such as redness, swelling, or itching. Patients may also experience skin thickening or dimpling at the injection site, itching, rash, swelling of the extremities (hands and feet), and weight gain. The prescribing information also highlights serious potential risks, including severe allergic reactions, hypokalemia (low potassium levels), and the exacerbation of heart failure when Onswik is used concurrently with thiazolidinediones (TZDs), a class of oral diabetes medications. Recognizing the signs of low blood sugar is paramount for patient safety. These symptoms can include shakiness, sweating, dizziness, confusion, blurred vision, rapid heartbeat, and a sensation of hunger.
The dosing mechanism of Onswik presents a unique aspect that necessitates careful attention to avoid errors. The Onswik KwikPen is available in two concentrated strengths, capable of delivering up to 400 or 800 units in a single injection. Eli Lilly strongly advises patients against withdrawing insulin from the pen using a syringe and emphasizes the importance of verifying the pen’s label before each administration to prevent accidental mix-ups. Individuals with visual impairments or blindness should not use the pen without the assistance of a trained caregiver.
Onswik is not intended for use in insulin pumps and should never be injected intravenously or intramuscularly. Pregnant or breastfeeding individuals should consult with their healthcare provider to discuss the potential risks and benefits, as the drug’s safety during these periods has not been established. Eli Lilly also cautions patients against driving or operating heavy machinery until they have a clear understanding of how Onswik affects their individual response, particularly concerning potential impacts on alertness and reaction time.
Dr. Kenneth Custer, Ph.D., Executive Vice President and President of Lilly Cardiometabolic Health, articulated the significance of this advancement, stating, "delays in initiating treatment and the burden of daily injections can have a real impact on patients’ day-to-day experience managing type 2 diabetes." The shift to a weekly injection schedule translates to approximately 52 injections per year, a substantial reduction from the roughly 365 injections associated with daily regimens. In the event of a missed dose, it is recommended to administer it as soon as possible, provided there are more than four days until the next scheduled dose, and then resume the regular weekly schedule. Patients are strongly advised against altering or switching their insulin regimen without professional medical guidance.
Eli Lilly anticipates that the Onswik KwikPen will become available in U.S. pharmacies within the coming months. The company has not yet disclosed the pricing strategy for Onswik, and coverage decisions by insurance providers remain to be determined. The introduction of the first weekly basal insulin, Awiqli, reached approximately 70,000 U.S. pharmacies upon its launch, and the competitive landscape may influence future pricing dynamics for Onswik.
For individuals who find adherence to daily insulin injections challenging, discussing the suitability of a weekly insulin regimen with their healthcare provider is a prudent step. Key questions to explore include understanding how to recognize and manage low blood sugar, the appropriate course of action for missed doses, and how pre-existing conditions such as kidney or liver impairment, heart failure, pregnancy plans, or concurrent TZD use might influence the decision-making process. Severe hypoglycemic episodes, characterized by confusion, fainting, or seizures, necessitate immediate emergency medical attention.
Onswik has also secured regulatory approval in international markets, including the European Union, Mexico, and Japan. The long-term impact of Onswik on diabetes management will be further shaped by the accumulation of real-world safety data, evolving pricing structures, and the decisions made by insurance companies regarding its reimbursement.
Key Questions Answered
What did the FDA approve?
The FDA has approved Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes, to be used in conjunction with diet and exercise.
Can people with type 1 diabetes use it?
No, Onswik is not recommended for individuals with type 1 diabetes due to an increased risk of severe low blood sugar (hypoglycemia).
Is it better than daily insulin?
Clinical trials indicated that Onswik lowers A1C levels comparably to daily insulins; it is not proven to be more effective. Rates of moderate-to-severe low blood sugar were similar across most trials, with a lower incidence observed in one trial with Onswik.
What are the main side effects?
The primary side effects include low blood sugar, allergic reactions, injection-site reactions, changes in skin at the injection site, itching, rash, swelling of the hands and feet, and weight gain.
When will it be available and how much will it cost?
Eli Lilly expects Onswik to be available in U.S. pharmacies in the coming months. The price has not been announced, and insurance coverage details are still pending.
